• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 11-K filed by Boston Scientific Corporation

    6/24/26 4:05:29 PM ET
    $BSX
    Medical/Dental Instruments
    Health Care
    Get the next $BSX alert in real time by email
    bsc-20260624
    FalseFalse00008857250000885725P1Yiso4217:USDxbrli:purebsc:agesbsc:yearxbrli:shares0000885725bsc:EBP001Member2025-01-012025-12-3100008857252025-01-012025-12-310000885725bsc:EBP001Member2025-12-310000885725bsc:EBP001Member2024-12-310000885725bsc:EBP001Memberbsc:AxonicsModulationTechnologiesInc.Member2025-01-012025-12-310000885725bsc:EBP001Memberbsc:BoltMedicalInc.Member2025-01-012025-12-310000885725bsc:EBP001Membersrt:MinimumMember2025-01-012025-12-310000885725bsc:EBP001Membersrt:MaximumMember2025-01-012025-12-310000885725bsc:EBP001Member2024-08-012025-12-310000885725bsc:EBP001Member2024-07-310000885725bsc:EBP001Member2024-01-012024-12-310000885725us-gaap:MutualFundMemberbsc:EBP001Memberus-gaap:FairValueInputsLevel1Member2025-12-310000885725us-gaap:DefinedBenefitPlanCommonCollectiveTrustMemberbsc:EBP001Memberus-gaap:FairValueInputsLevel1Member2025-12-310000885725us-gaap:CommonStockMemberbsc:EBP001Memberus-gaap:FairValueInputsLevel1Member2025-12-310000885725bsc:EBP001Memberus-gaap:FairValueInputsLevel1Member2025-12-310000885725us-gaap:MutualFundMemberbsc:EBP001Memberus-gaap:FairValueInputsLevel1Member2024-12-310000885725us-gaap:DefinedBenefitPlanCommonCollectiveTrustMemberbsc:EBP001Memberus-gaap:FairValueInputsLevel1Member2024-12-310000885725us-gaap:CommonStockMemberbsc:EBP001Memberus-gaap:FairValueInputsLevel1Member2024-12-310000885725bsc:EBP001Memberus-gaap:FairValueInputsLevel1Member2024-12-310000885725bsc:EBP001MemberVanguard Group | Institutional 500 Index Trust A | Common Collective Trust2025-12-310000885725bsc:EBP001MemberVanguard Group | Institutional Extended Market Index Trust A | Common Collective Trust2025-12-310000885725bsc:EBP001MemberVanguard Group | Institutional Total Bond Market Index Trust A | Common Collective Trust2025-12-310000885725bsc:EBP001MemberVanguard Group | Institutional Total International Stock Market Index Trust A | Common Collective Trust2025-12-310000885725bsc:EBP001MemberVanguard Group | Target Retirement 2020 Trust Select | Common Collective Trust2025-12-310000885725bsc:EBP001MemberVanguard Group | Target Retirement 2025 Trust Select | Common Collective Trust2025-12-310000885725bsc:EBP001MemberVanguard Group | Target Retirement 2030 Trust Select | Common Collective Trust2025-12-310000885725bsc:EBP001MemberVanguard Group | Target Retirement 2035 Trust Select | Common Collective Trust2025-12-310000885725bsc:EBP001MemberVanguard Group | Target Retirement 2040 Trust Select | Common Collective Trust2025-12-310000885725bsc:EBP001MemberVanguard Group | Target Retirement 2045 Trust Select | Common Collective Trust2025-12-310000885725bsc:EBP001MemberVanguard Group | Target Retirement 2050 Trust Select | Common Collective Trust2025-12-310000885725bsc:EBP001MemberVanguard Group | Target Retirement 2055 Trust Select | Common Collective Trust2025-12-310000885725bsc:EBP001MemberVanguard Group | Target Retirement 2060 Trust Select | Common Collective Trust2025-12-310000885725bsc:EBP001MemberVanguard Group | Target Retirement 2065 Trust Select | Common Collective Trust2025-12-310000885725bsc:EBP001MemberVanguard Group | Target Retirement 2070 Trust Select | Common Collective Trust2025-12-310000885725bsc:EBP001MemberVanguard Group | Target Retirement Income Trust Select | Common Collective Trust2025-12-310000885725bsc:EBP001MemberVanguard Group | Target Retirement Income and Growth Trust Select | Common Collective Trust2025-12-310000885725bsc:EBP001MemberVanguard Group | Target Retirement Income Fund | Mutual Fund2025-12-310000885725bsc:EBP001MemberVanguard Group | 500 Index Adm | Mutual Fund2025-12-310000885725bsc:EBP001MemberVanguard Group | Growth Index Adm | Mutual Fund2025-12-310000885725bsc:EBP001MemberVanguard Group | Total Stock Market Index Adm | Mutual Fund2025-12-310000885725bsc:EBP001MemberVanguard Group | Mid-Cap Growth Index Adm | Mutual Fund2025-12-310000885725bsc:EBP001MemberVanguard Group | Total Intl Stock Index Adm | Mutual Fund2025-12-310000885725bsc:EBP001MemberVanguard Group | Small-Cap Growth Index Adm | Mutual Fund2025-12-310000885725bsc:EBP001MemberVanguard Group | Small-Cap Value Index Adm | Mutual Fund2025-12-310000885725bsc:EBP001MemberVanguard Group | Real Estate Index Adm | Mutual Fund2025-12-310000885725bsc:EBP001MemberVanguard Group | Balanced Index Adm | Mutual Fund2025-12-310000885725bsc:EBP001MemberVanguard Group | Value Index Adm | Mutual Fund2025-12-310000885725bsc:EBP001MemberVanguard Group | Mid Cap Index Adm | Mutual Fund2025-12-310000885725bsc:EBP001MemberVanguard Group | Small-Cap Index Adm | Mutual Fund2025-12-310000885725bsc:EBP001MemberVanguard Group | Mid-Cap Value Index Adm | Mutual Fund2025-12-310000885725bsc:EBP001MemberVanguard Group | Emerging Mkts Stock Idx Adm | Mutual Fund2025-12-310000885725bsc:EBP001MemberVanguard Group | Total Bond Market Index Adm | Mutual Fund2025-12-310000885725bsc:EBP001MemberVanguard Group | Cash Reserves Federal MM Adm | Mutual Fund2025-12-310000885725bsc:EBP001MemberVanguard Group | Short-Term Bond Index Adm | Mutual Fund2025-12-310000885725bsc:EBP001MemberVanguard Group | Total Intl Bond Index Adm | Mutual Fund2025-12-310000885725bsc:EBP001MemberVanguard Group | T. Rowe Price U.S. Value Equity Trust; Class C | Common Collective Trust2025-12-310000885725bsc:EBP001MemberVanguard Group | Capital Group EuroPacific Growth Trust; U2 | Common Collective Trust2025-12-310000885725bsc:EBP001MemberVanguard Group | Fidelity (FIAM) Core Plus CIT; Class J | Common Collective Trust2025-12-310000885725bsc:EBP001MemberVanguard Group | Legal & General S&P 500 Dc Cit | Common Collective Trust2025-12-310000885725bsc:EBP001MemberVanguard Group | State St Intl Indx Sl Cl Ix | Common Collective Trust2025-12-310000885725bsc:EBP001MemberVanguard Group | State St Us Bnd Indx Sl Cl Xiv | Common Collective Trust2025-12-310000885725bsc:EBP001MemberVanguard Group | Legal & General S&P 400 Dc Cit B | Common Collective Trust2025-12-310000885725bsc:EBP001MemberVanguard Group | State St Emg Mkts Indx Sl Sf Cl Ii | Common Collective Trust2025-12-310000885725bsc:EBP001MemberVanguard Group | Legal & General S&P 600 Dc Cit | Common Collective Trust2025-12-310000885725bsc:EBP001MemberVanguard Group | T Rowe Price Institutional Sm. Cap Stock Fund: Inst'l Cl | Mutual Fund2025-12-310000885725bsc:EBP001MemberVanguard Group | JPMorgan Large Cap Growth Fund; Class R6 | Mutual Fund2025-12-310000885725bsc:EBP001MemberVanguard Group | American Funds New Perspective R6 | Mutual Fund2025-12-310000885725bsc:EBP001MemberVanguard Group | American Funds Eupac R6 | Mutual Fund2025-12-310000885725bsc:EBP001MemberVanguard Group | Baird Aggregate Bond Inst | Mutual Fund2025-12-310000885725bsc:EBP001MemberVanguard Group | Fidelity Real Estate Index | Mutual Fund2025-12-310000885725bsc:EBP001MemberVanguard Group | Nomura Small Cap Value R6 | Mutual Fund2025-12-310000885725bsc:EBP001MemberVanguard Group | American Cent Us Sm Cap Growth Trst Cl F | Mutual Fund2025-12-310000885725bsc:EBP001MemberVanguard Group | Dreyfus Government Cash Mgmt Instl | Mutual Fund2025-12-310000885725bsc:EBP001MemberStable Value Fund | Vanguard Retirement Savings Trust II | Common Collective Trust2025-12-310000885725bsc:EBP001MemberStable Value Fund | PUTNAM STABLE VALUE FUND | Common Collective Trust2025-12-310000885725bsc:EBP001MemberStable Value Fund | Boston Scientific Common Stock Fund Shares | Common Stock2025-12-31



    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM 11-K
    FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE,
    SAVINGS AND SIMILAR PLANS PURSUANT TO
    SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
    (Mark One):
    þANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
    For the fiscal year ended December 31, 2025
    OR
    oTRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
    For the transition period from to
       Commission file number: 1-11083
     A.Full title of the plan and the address of the plan, if different from that of the issuer named below:
    Boston Scientific Corporation
    401(k) Retirement Savings Plan
     B.Name of issuer of the securities held pursuant to the plan and the address of its principal executive
    office:
    Boston Scientific Corporation
    300 Boston Scientific Way
    Marlborough, MA 01752













    Boston Scientific Corporation 401(k) Retirement Savings Plan


    Audited Financial Statements
    and Supplemental Schedule


    As of December 31, 2025 and 2024 and for the Year Ended December 31, 2025


    Table of Contents

                    
    Report of Independent Registered Public Accounting Firm
    1
    Audited Financial Statements
    Statements of Net Assets Available for Benefits    
    2
    Statement of Changes in Net Assets Available for Benefits
    3
    Notes to the Audited Financial Statements
    4
    Supplemental Schedule
    Schedule H, Line 4i - Schedule of Assets (Held at End of Year)
    10
    Signatures
    12
    Exhibit Index
    13







    Report of Independent Registered Public Accounting Firm

    To the Plan Participants and the Plan Administrator of Boston Scientific Corporation 401(k) Retirement Savings Plan

    Opinion on the Financial Statements

    We have audited the accompanying statements of net assets available for benefits of Boston Scientific Corporation 401(k) Retirement Savings Plan (the Plan) as of December 31, 2025 and 2024, and the related statement of changes in net assets available for benefits for the year ended December 31, 2025, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the net assets available for benefits of the Plan at December 31, 2025 and 2024, and the changes in its net assets available for benefits for the year ended December 31, 2025, in conformity with U.S. generally accepted accounting principles.

    Basis for Opinion

    These financial statements are the responsibility of the Plan’s management. Our responsibility is to express an opinion on the Plan’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Plan in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

    We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Plan is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Plan’s internal control over financial reporting. Accordingly, we express no such opinion.

    Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

    Supplemental Schedule Required by ERISA

    The accompanying supplemental schedule of assets (held at end of year) as of December 31, 2025 (referred to as the "supplemental schedule"), has been subjected to audit procedures performed in conjunction with the audit of the Plan’s financial statements. The information in the supplemental schedule is the responsibility of the Plan’s management. Our audit procedures included determining whether the information reconciles to the financial statements or the underlying accounting and other records, as applicable, and performing procedures to test the completeness and accuracy of the information presented in the supplemental schedule. In forming our opinion on the information, we evaluated whether such information, including its form and content, is presented in conformity with the Department of Labor’s Rules and Regulations for Reporting and Disclosure under the Employee Retirement Income Security Act of 1974. In our opinion, the information is fairly stated, in all material respects, in relation to the financial statements as a whole.


    /s/ Ernst & Young LLP


    We have served as the Plan’s auditor since 1996.
    Boston, Massachusetts
    June 24, 2026


    1


    Statements of Net Assets Available for Benefits

    As of December 31,
    (in thousands)20252024
    Assets
    Investments, at fair value$7,863,016 $6,739,594 
    Receivables:
          Participant contributions60 21 
          Employer contributions373 689 
          Notes receivable from participants38,794 35,465 
    Total receivables39,227 36,175 
    Net assets available for benefits$7,902,243 $6,775,769 

        

    See accompanying Notes to the Audited Financial Statements.


























    2


    Statement of Changes in Net Assets Available for Benefits

    (in thousands)Year Ended December 31, 2025
    Additions
       Investment income:
          Interest and dividends$47,317 
          Net appreciation in fair value of investments1,048,988 
    1,096,305 
       Interest income on notes receivable from participants2,924 
       Assets transferred in81,921 
       Other income8 
       Contributions:
          Participants247,580 
          Employer162,076 
          Participant rollovers48,671 
    458,327 
    Total additions1,639,485 
    Deductions
       Benefit payments510,007 
       Administrative expenses3,004 
    Total deductions513,011 
    Net increase1,126,474 
    Net assets available for benefits:
          Beginning of year6,775,769 
          End of year$7,902,243 
        


    See accompanying Notes to the Audited Financial Statements.









    3

    Notes to the Audited Financial Statements

    NOTE 1 - DESCRIPTION OF THE PLAN

    The following description of the Boston Scientific Corporation 401(k) Retirement Savings Plan, as amended (the Plan), provides only general information. Participants should refer to the Summary Plan Description and the Plan document for a more complete description of the Plan's provisions. Copies of these documents are available from the Employee Benefits Committee (the Committee). Capitalized terms used in this description not otherwise defined herein shall each have the meanings set forth in the Plan.

    General
    The Plan is a defined contribution plan covering all Eligible Employees who have completed an Hour of Service and have attained 18 years of age. If, as a result of temporary or short-term employment at Boston Scientific Corporation (the Company), an employee satisfies the minimum service requirement for the Plan, the employee will be considered an Eligible Employee for purposes of the Plan. A Participant is an Employee who satisfies the eligibility requirements of the Plan and contributes to the Plan. The Plan is subject to the provisions of the Employee Retirement Income Security Act of 1974 (ERISA), as amended. The Plan year is defined as the calendar year.

    The Plan is administered by the Committee, whose members are appointed by the Chief Executive Officer of the Company. Vanguard Fiduciary Trust Company (Vanguard) is a fiduciary and trustee of the Plan as well as the recordkeeper of each Plan Participant's account. CapTrust is the independent fiduciary and investment manager for the Boston Scientific Corporation Company Stock Fund (Company Stock Fund).

    Plan Mergers
    The Company completed acquisitions of Axonics, Inc. and Bolt Medical Inc. during 2025. In connection with these transactions, net assets of approximately $74 million from the Axonics Modulation Technologies, Inc. 401(k) Plan and $6 million from the TriNet 401k Bolt Medical, Inc. Plan were merged into the Plan during 2025 and are reflected as assets transferred in within the 2025 Statement of Changes in Net Assets Available for Benefits.

    Contributions
    The Plan satisfies the requirements of a safe harbor plan, in accordance with Internal Revenue Code (IRC) Section 401(k)(12)(B). An Eligible Employee may contribute between 1% and 50% of their Eligible Compensation to the Plan as Elective Deferrals, up to established federal limits indexed annually. Elective Deferrals include pre-tax contributions and Roth contributions. If elected, Roth contributions are combined with all annual pre-tax contributions in determining the maximum amount which a Participant may contribute to Elective Deferrals each year. Participants are not permitted to make contributions on a traditional after-tax basis. Participants aged 50 or older by December 31, 2025 are also eligible to contribute additional catch-up contributions, up to established federal limits.

    The Plan provides for Automatic Enrollments, whereby an Eligible Employee who completes an Hour of Service with the Company and who would otherwise have been eligible to make Elective Deferrals but did not, is enrolled in the Plan 30 days after the employee satisfies the Plan's eligibility requirements. This feature automatically enrolls each Eligible Employee into the Plan at a default contribution rate of 2% of their Eligible Compensation on a pre-tax basis for the first Plan year. Contributions are allocated to the Qualified Default Investment Alternative (QDIA) fund. Following the first Plan year, the rate of contribution of an Eligible Employee's Compensation under the automatic enrollment increases annually in 1% increments, up to a maximum of 6% in the fifth Plan year in which the Automatic Compensation Reduction Authorization is in effect. Participants receive advance notice of their right to elect not to participate in either of these automatic Plan features and are permitted to stop or change either feature at any time.

    Vanguard Target Retirement Trust Select Funds represent the QDIA fund for the Plan. In the event contributions are made on behalf of a Participant for whom there are no fund allocations elected, the contributions and any associated matching contribution will be allocated to the applicable Target Retirement Trust Select Fund that is closest to the year in which the Participant reaches the age of 65.

    The Company matches Elective Deferrals at a rate of 200% for the first 2% of the Participant's Eligible Compensation during the Plan year and 50% of the Elective Deferrals thereafter up to a maximum of 6% of the Participant's Eligible Compensation. The Company has the right under the Plan to discontinue or modify its matching contributions at any time. In addition, the Company's Board of Directors may approve additional discretionary contributions to the Plan. No discretionary contributions were made during 2025.



    4


    The Plan invests in common stock of the Company through its Company Stock Fund. The Company Stock Fund may also hold cash or other short-term securities, although these are expected to be a small percentage of the fund. Since August 1, 2024, Participants and any newly eligible Employees may only allocate up to 50% of future account contributions to the Company Stock Fund. Any Participant who, as of July 31, 2024, allocated more than 50% of future account contributions to the Company Stock Fund may retain such Company Stock Fund allocation percentage but will automatically be reduced to a 50% contribution allocation percentage upon any change to the Participant’s investment allocations for account contributions that occur on or after August 1, 2024.

    Each Participant is entitled to exercise voting rights attributable to the shares allocated to their account and is notified by the Company prior to the time that such rights may be exercised. The trustee votes any allocated shares for which instructions have not been given by a Participant in the same proportion as the shares of the Company Stock Fund for which the trustee has received timely Participant directions, unless the Committee directs the trustee otherwise. Participants have the same voting rights in the event of a tender or exchange offer.
    Participant Accounts and Vesting
    A Participant can allocate their account among various investment funds. Each Participant's account is credited with the Participant's contribution, the Company's contribution, and an allocation of the earnings and losses for the Participant's particular investment funds. Under current Plan rules, each Participant is fully vested immediately in their contributions and Company contributions.
    Notes Receivable from Participants
    Subject to certain limitations, a Participant may borrow from their account a minimum of $1,000 and up to a maximum equal to the lesser of $50,000 or 50% of their vested account balance. Loan terms range from one to five years in most instances, or up to ten years if the loan is for the purchase of a primary residence. However, Participants of the defined contribution plans of acquired companies must retain the loan terms granted under their former plans. Loans are secured by the balance in the Participant's account and bear an interest rate of Prime plus 1%. The interest rate is updated monthly and is applied as of the first day of the month in which the loan is confirmed. Principal and interest are repaid ratably through automatic payroll deductions. Terminated Participants may continue to make loan repayments directly to Vanguard for the duration of their loan term.

    Payment of Benefits
    Employees and beneficiaries are eligible to receive distributions in the form of installments, partial payments or a lump-sum. The Company Stock Fund may be distributed in-kind, if requested by the Participant. Upon termination, Participant account balances (less any rollover amounts) in excess of $7,000 may continue to be invested in the Plan until the Participant attains the age of 72. While employed by the Company, a Participant may withdraw all or a portion of their Elective Contributions to the extent necessary to meet a financial hardship, as provided for in the Plan, not to exceed one financial hardship withdrawal per year. Financial hardship withdrawals are strictly regulated by the Internal Revenue Service (IRS). Qualified Disaster Relief Withdrawals permit special hardship distributions only (but not loans) for previously approved and any future disaster reliefs granted by the IRS. Participants may make withdrawals for any reason after attaining age 59½. Disabled Participants as defined in the Company's group long-term disability contract are allowed to make withdrawals at any time regardless of age. The Plan also allows withdrawals regardless of age from a Participant's after-tax account for any reason.

    Forfeitures
    Unallocated and forfeited non-vested accounts were $96,181 and $15,609 as of December 31, 2025 and 2024, respectively. These amounts are used to: (a) restore any amount previously forfeited as required by applicable regulations, (b) pay reasonable expenses of administering the Plan and (c) reduce future employer matching contributions. In 2025, employer contributions were reduced by forfeited non-vested accounts in the amount of $37,254 and no forfeitures were restored to Participants.

    Administrative Expenses
    Certain of the Plan's administrative expenses, including recordkeeping and trustee fees, are paid by Plan Participants through a quarterly fee of $4.25 charged to each Participant's account. Expenses relating to purchases, sales, or transfers of the Plan's investments are charged to the particular investment fund to which the expenses relate. The Company pays all other administrative expenses of the Plan. The quarterly fees charged to Participants are used to offset Plan expenses. Any unused fees are maintained in an unallocated asset account, which totaled $8,281 and $320,386 as of December 31, 2025 and 2024, respectively. During 2025, $347,262 of such unallocated funds were used to offset administrative expenses.



    5


    Plan Termination
    Although it has not expressed any intent to do so, the Company has the right under the Plan to discontinue its contributions at any time and to terminate the Plan subject to the provisions of ERISA. In the event of a termination of the Plan, the assets shall be liquidated and distributed in accordance with the provisions of the Plan and as prescribed by ERISA and the regulations pursuant thereto. Upon termination of the Plan, the Participants will become fully vested in any non-vested portion of their accounts.

    NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

    Basis of Presentation
    The accompanying financial statements have been prepared on the accrual basis of accounting in conformity with U.S. generally accepted accounting principles (U.S. GAAP). Amounts in the financial statements are presented in thousands of dollars. Prior-year amounts have been presented on a consistent basis to conform to the current year presentation, with no impact on previously reported results. Amounts reported in thousands within this report are computed based on exact amounts.

    Use of Estimates
    The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and accompanying notes and supplemental schedule, and the reported amounts of additions and deductions during the reporting period. Actual results could differ from those estimates.

    Contributions
    Participant contributions and the matching employer contributions are recorded in the year in which the participant contributions are withheld from compensation.

    Payment of Benefits
    Benefits are recorded when paid.

    Notes Receivable from Participants
    Notes receivable from Participants represent Participant loans that are recorded at their unpaid principal balance, plus any accrued but unpaid interest. Interest income on notes receivable from Participants is recorded when it is earned. Related fees are recorded as administrative expenses and are expensed when they are incurred. No allowance for credit losses has been recorded as of December 31, 2025 or 2024. If a Participant ceases to make loan repayments and the Plan Administrator deems the loan to be a distribution, the loan balance is reduced and a benefit payment is recorded.

    Investment Valuation and Income Recognition
    The Plan's investments are stated at fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (an exit price). See Note 3, Fair Value Measurements, for additional information. The Committee is responsible for determining the Plan's investment strategy and analyzing information provided by the investment custodians and issuers that is used to determine the fair value of the Plan's investments.

    Purchases and sales of securities are recorded on a trade-date basis. Interest income is accrued when earned. Net appreciation includes the Plan's gains and losses on investments bought, sold and held during the year. Dividend income is recorded on the ex-dividend date. Capital gain distributions are included within dividend income.

    NOTE 3 - FAIR VALUE MEASUREMENTS

    Accounting Standards Codification 820, Fair Value Measurement, establishes a three-level valuation hierarchy for disclosure of fair value measurements. Financial assets and financial liabilities are categorized within the valuation hierarchy based upon the lowest level of input that is significant to the measurement of fair value. The three levels of the hierarchy are defined as follows:

    Level 1 - inputs to the valuation methodology are quoted market prices for identical assets or liabilities.

    Level 2 - inputs to the valuation methodology are other observable inputs, including quoted market prices for similar assets or liabilities and market-corroborated inputs.

    6


    Level 3 - inputs to the valuation methodology are unobservable inputs, based on management's best estimate of inputs market participants would use in pricing the asset or liability at the measurement date, including assumptions about risk.


    The following is a description of the valuation methodologies used for assets measured at fair value. The Plan's valuation methodology used to measure the fair value of common stock and mutual funds was derived from quoted market prices, as substantially all of these instruments have active markets. The investments in the common collective trusts are stated at fair value, based on the year-end market value of each unit held, using net asset value, which is derived from the market value of the underlying net assets.

    The Plan's investments measured at fair value consist of the following:

    As of December 31, 2025
    (in thousands)Level 1
    Mutual funds$436,381 
    Common collective trusts6,903,464 
    Common stock523,171 
    Total investments at fair value$7,863,016 
    As of December 31, 2024
    (in thousands)Level 1
    Mutual funds$430,785 
    Common collective trusts5,769,177 
    Common stock539,632 
    Total investments at fair value$6,739,594 

    NOTE 4 - TRANSACTIONS WITH PARTIES-IN-INTEREST

    The Plan invests in certain funds managed by an affiliate of Vanguard. As described in Note 1 - Description of the Plan, Vanguard is a fiduciary and trustee of the Plan as well as the recordkeeper which maintains the individual accounts of each Participant. The Plan also invests in the common stock of the Company. Transactions in these investments qualify as party-in-interest transactions; however, they are exempt from the prohibited transaction rules under ERISA. The Company paid plan related fees for legal, accounting and other services rendered during the year by parties-in-interest.

    NOTE 5 - RISKS AND UNCERTAINTIES

    The Plan and its Participants invest in various investment securities. Investment securities are exposed to various risks, such as overall market volatility, interest rate, liquidity and credit risks. Due to the level of risk associated with certain investment securities, it is at least reasonably possible that changes in the values of investment securities will occur in the near term and that such changes could materially affect Participants' account balances and the amounts reported within the Statements of Net Assets Available for Benefits.

    NOTE 6 - INCOME TAX STATUS

    The Plan has received a determination letter from the IRS, dated April 27, 2017, stating that the Plan, as amended and restated, is qualified under Section 401(a) of the IRC, and, therefore, the related trust is exempt from taxation. Subsequent to this determination by the IRS, the Plan was amended and restated. Once qualified, the Plan is required to operate in conformity with the IRC to maintain its qualified status. The plan administrator believes the Plan is being operated in compliance with the applicable requirements of the IRC and, therefore, believes that the Plan, as amended and restated, is qualified and the related trust is tax exempt.
    U.S. GAAP requires plan management to evaluate tax positions taken by the Plan and recognize a tax liability if the Plan has taken an uncertain position that more likely than not would not be sustained upon examination by the IRS. Plan management has analyzed the tax positions taken by the Plan, and has concluded that there are no uncertain positions taken or expected to be taken. The Plan is subject to routine audits by taxing jurisdictions; however, there are currently no audits for any tax periods in progress.
    7


    NOTE 7 - RECONCILIATION OF FINANCIAL STATEMENTS TO FORM 5500

    The following is a reconciliation of net assets available for benefits per the Statements of Net Assets Available for Benefits to net assets available for benefits on the Form 5500:

    As of December 31,
    (in thousands)20252024
    Net assets available for benefits$7,902,243 $6,775,769 
    Deemed distributions(527)(480)
    Net assets available for benefits per the Form 5500$7,901,716 $6,775,289 


    The following is a reconciliation of changes in net assets available for benefits per the Statement of Changes in Net Assets Available for Benefits to net income on the Form 5500:

    (in thousands)Year Ended December 31, 2025
    Net increase$1,126,474 
    Deemed distributions(47)
    Net income (including transfers) per the Form 5500$1,126,427 

    NOTE 8 - SUBSEQUENT EVENTS

    After December 31, 2025, Boston Scientific Corporation's common stock experienced a significant decline in market value which affected the value of the Plan's Company Stock Fund. While plan assets invested in Company Stock have significantly decreased in value, this is a non-recognized subsequent event; accordingly, no changes were made to the accompanying financial statements.
    8




















    SUPPLEMENTAL SCHEDULE


    9


    Boston Scientific Corporation 401(k) Retirement Savings Plan
    EIN 04-2695240
    Plan #001

    Schedule H, Line 4i - Schedule of Assets (Held at End of Year)
    December 31, 2025
    (Amounts in thousands, except per share data)
    Identity of IssueDescriptionShares or UnitsCurrent Value
    *Vanguard Group
    Institutional 500 Index Trust ACommon Collective Trust13,584,517 $1,889,470 
    Institutional Extended Market Index Trust ACommon Collective Trust2,949,159 379,380
    Institutional Total Bond Market Index Trust ACommon Collective Trust3,368,846 371,112
    Institutional Total International Stock Market Index Trust ACommon Collective Trust2,628,711 368,966
    Target Retirement 2020 Trust SelectCommon Collective Trust1,007,036 57,293
    Target Retirement 2025 Trust SelectCommon Collective Trust2,764,112 170,244
    Target Retirement 2030 Trust SelectCommon Collective Trust5,035,547 333,371
    Target Retirement 2035 Trust SelectCommon Collective Trust5,811,820 403,080
    Target Retirement 2040 Trust SelectCommon Collective Trust5,741,061 427,614
    Target Retirement 2045 Trust SelectCommon Collective Trust6,328,674 485,009
    Target Retirement 2050 Trust SelectCommon Collective Trust5,668,671 457,398
    Target Retirement 2055 Trust SelectCommon Collective Trust4,590,725 371,677
    Target Retirement 2060 Trust SelectCommon Collective Trust2,889,085 233,558
    Target Retirement 2065 Trust SelectCommon Collective Trust1,446,676 70,428
    Target Retirement 2070 Trust SelectCommon Collective Trust175,302 5,220
    Target Retirement Income Trust SelectCommon Collective Trust1,074,484 50,934
    Target Retirement Income and Growth Trust SelectCommon Collective Trust63,844 1,653
    Target Retirement Income FundMutual Fund16,568 230
    500 Index AdmMutual Fund13,295 8,400
    Growth Index AdmMutual Fund25,611 6,432
    Total Stock Market Index AdmMutual Fund26,681 4,354
    Mid-Cap Growth Index AdmMutual Fund12,269 1,474
    Total Intl Stock Index AdmMutual Fund29,236 1,185
    Small-Cap Growth Index AdmMutual Fund9,121 968
    Small-Cap Value Index AdmMutual Fund8,810 802
    Real Estate Index AdmMutual Fund5,831 731
    Balanced Index AdmMutual Fund13,161 682
    Value Index AdmMutual Fund9,018 672
    Mid Cap Index AdmMutual Fund1,744 627
    Small-Cap Index AdmMutual Fund5,011 619
    Mid-Cap Value Index AdmMutual Fund6,632 609
    Emerging Mkts Stock Idx AdmMutual Fund12,696 566
    Total Bond Market Index AdmMutual Fund57,641 563
    Cash Reserves Federal MM AdmMutual Fund300,852 301
    Short-Term Bond Index AdmMutual Fund12,645 131
    Total Intl Bond Index AdmMutual Fund5,601 108
    T. Rowe Price U.S. Value Equity Trust; Class CCommon Collective Trust5,081,470 256,614
    Capital Group EuroPacific Growth Trust; U2Common Collective Trust15,794,975 249,877
    Fidelity (FIAM) Core Plus CIT; Class JCommon Collective Trust2,163,525 53,439
    10


    Legal & General S&P 500 Dc CitCommon Collective Trust3,501 1,172
    State St Intl Indx Sl Cl IxCommon Collective Trust11,422 219
    State St Us Bnd Indx Sl Cl XivCommon Collective Trust13,635 157
    Legal & General S&P 400 Dc Cit BCommon Collective Trust687 157
    State St Emg Mkts Indx Sl Sf Cl IiCommon Collective Trust6,824 110
    Legal & General S&P 600 Dc CitCommon Collective Trust333 75
    T Rowe Price Institutional Sm. Cap Stock Fund: Inst'l ClMutual Fund10,780,004 262,818
    JPMorgan Large Cap Growth Fund; Class R6Mutual Fund1,660,003 143,491
    American Funds New Perspective R6Mutual Fund4,260 301
    American Funds Eupac R6Mutual Fund1,839 111
    Baird Aggregate Bond InstMutual Fund7,342 73
    Fidelity Real Estate IndexMutual Fund4,108 66
    Nomura Small Cap Value R6Mutual Fund841 56
    American Cent Us Sm Cap Growth Trst Cl FMutual Fund887 10
    Dreyfus Government Cash Mgmt InstlMutual Fund515 1
    Stable Value Fund:
    *Vanguard Retirement Savings Trust IICommon Collective Trust264,864,624 264,865
    PUTNAM STABLE VALUE FUNDCommon Collective Trust371,933 372
    *Boston Scientific Common Stock Fund SharesCommon Stock8,707,903 523,171
    *Notes Receivable from Participants, interest rates 4.25% - 9.5%
    Loan38,794
    $7,901,810 
    * Indicates party-in-interest to the Plan.

    Note: Cost information is not presented, because all investments are Participant-directed.



    11


    SIGNATURES



        Pursuant to the requirements of the Securities Exchange Act of 1934, the trustee (or other persons who administer the employee benefit plan) has duly caused this Annual Report to be signed on its behalf by the undersigned thereunto duly authorized on June 24, 2026.

    BOSTON SCIENTIFIC CORPORATION
    401(K) RETIREMENT SAVINGS PLAN
    By:/s/ Gail Beauregard
    Name: Gail Beauregard
    Title: Vice President, Global Total Rewards
                Member, Employee Benefits Committee



























    12


    EXHIBIT INDEX


    Exhibit NumberDescription
    23
    Consent of Independent Registered Public Accounting Firm

































    13
    Get the next $BSX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BSX

    DatePrice TargetRatingAnalyst
    5/29/2026Outperform → Peer Perform
    Wolfe Research
    5/28/2026$55.00Overweight → Equal Weight
    Wells Fargo
    3/30/2026$88.00Strong Buy → Outperform
    Raymond James
    10/3/2025Buy → Hold
    Erste Group
    9/8/2025$125.00Perform → Outperform
    Oppenheimer
    6/16/2025$118.00Outperform
    Leerink Partners
    4/16/2025$113.00Hold → Buy
    Needham
    1/10/2025$108.00Hold → Buy
    Deutsche Bank
    More analyst ratings

    $BSX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    FRACTURE IDE trial of the Boston Scientific SEISMIQ™ 4CE Coronary Intravascular Lithotripsy Catheter meets primary safety and effectiveness endpoints

    Late-breaking data from global pivotal study achieved high rates of freedom from major adverse cardiac events and procedural success in patients with severe coronary artery diseaseMARLBOROUGH, Mass. and PARIS, May 19, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) today announced positive results from the pivotal FRACTURE Investigational Device Exemption (IDE) trial evaluating the use of the SEISMIQ™ 4CE Coronary Intravascular Lithotripsy Catheter* to treat patients with severely calcified coronary artery disease (CAD). The study met its primary safety and effectiveness endpoints, demonstrating high rates of freedom from major adverse cardiac events (MACE) at 30 days as well a

    5/19/26 6:31:00 AM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    Boston Scientific enters into $2 billion accelerated share repurchase agreement

    MARLBOROUGH, Mass., May 18, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) today announced that it has entered into an accelerated share repurchase (ASR) agreement with JPMorgan Chase Bank, National Association for $2 billion (the repurchase price) of its common stock, as part of its previously announced $5 billion share repurchase authorization. Under the terms of the ASR, Boston Scientific will pay the repurchase price and receive common stock with an aggregate value of 80% of the repurchase price based on the closing share price of the company's common stock as of May 15, 2026: this represents approximately 30.4 million shares based on the May 15, 2026, closing price of $52

    5/18/26 7:00:00 AM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    Boston Scientific announces strategic investment in MiRus LLC

    Agreement includes exclusive option to acquire novel, balloon-expandable transcatheter aortic valve made with proprietary rhenium alloyMARLBOROUGH, Mass., May 18, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) today announced it has invested $1.5 billion in return for an approximately 34% equity stake in MiRus LLC, a privately-held company developing and commercializing proprietary biomaterials, implants and procedural solutions for the treatment of cardiovascular and orthopedic diseases, including the SIEGEL™ Balloon Expandable Transcatheter Aortic Valve Replacement (TAVR) system. As part of the investment agreement, Boston Scientific also received an exclusive option to acqu

    5/18/26 6:30:00 AM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    $BSX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Boston Scientific downgraded by Wolfe Research

    Wolfe Research downgraded Boston Scientific from Outperform to Peer Perform

    5/29/26 8:06:22 AM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    Boston Scientific downgraded by Wells Fargo with a new price target

    Wells Fargo downgraded Boston Scientific from Overweight to Equal Weight and set a new price target of $55.00

    5/28/26 8:45:02 AM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    Boston Scientific downgraded by Raymond James with a new price target

    Raymond James downgraded Boston Scientific from Strong Buy to Outperform and set a new price target of $88.00

    3/30/26 8:15:23 AM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    $BSX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chairman, President & CEO Mahoney Michael F gifted 386,755 shares (SEC Form 4)

    4 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)

    6/1/26 4:18:00 PM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    Director Ludwig Edward J bought $202,914 worth of shares (3,580 units at $56.68), increasing direct ownership by 16% to 25,359 units (SEC Form 4)

    4 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)

    5/21/26 5:21:10 PM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    Director Pegus Cheryl bought $99,987 worth of shares (1,770 units at $56.49) (SEC Form 4)

    4 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)

    5/21/26 5:21:12 PM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    $BSX
    SEC Filings

    View All

    SEC Form 11-K filed by Boston Scientific Corporation

    11-K - BOSTON SCIENTIFIC CORP (0000885725) (Filer)

    6/24/26 4:05:29 PM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    SEC Form SD filed by Boston Scientific Corporation

    SD - BOSTON SCIENTIFIC CORP (0000885725) (Filer)

    5/21/26 4:16:28 PM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    Boston Scientific Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - BOSTON SCIENTIFIC CORP (0000885725) (Filer)

    5/18/26 7:17:15 AM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    $BSX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Ludwig Edward J bought $202,914 worth of shares (3,580 units at $56.68), increasing direct ownership by 16% to 25,359 units (SEC Form 4)

    4 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)

    5/21/26 5:21:10 PM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    Director Pegus Cheryl bought $99,987 worth of shares (1,770 units at $56.49) (SEC Form 4)

    4 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)

    5/21/26 5:21:12 PM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    Director Habiger David C bought $251,098 worth of shares (4,450 units at $56.43), increasing direct ownership by 47% to 13,878 units (SEC Form 4)

    4 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)

    5/21/26 5:20:09 PM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    $BSX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    March 1, 2024 - FDA Roundup: March 1, 2024

    For Immediate Release: March 01, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA issued a letter of enforcement discretion for certain qualified health claims regarding the consumption of yogurt and the reduced risk of type 2 diabetes. The letter states that the FDA does not intend to object to the use of these claims, provide

    3/1/24 4:00:21 PM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    $BSX
    Leadership Updates

    Live Leadership Updates

    View All

    CathVision Announces Appointment of Eric Thepaut as Independent Chairman of the Board and Releases ECGenius® System Version 3.5

    COPENHAGEN, Denmark, Dec. 10, 2025 /PRNewswire/ -- CathVision, a medical technology company dedicated to improving clinical outcomes in cardiac electrophysiology through high-fidelity signal acquisition and intelligent software, today announced two major milestones: the appointment of Eric Thepaut as independent Chairman of the Board, and the commercial release of Version 3.5 of the ECGenius® System. Eric Thepaut Appointed Independent Chairman of the Board Eric Thepaut joins CathVision following his recent retirement from Boston Scientific Corporation (NYSE:BSX), where he serv

    12/10/25 4:00:00 AM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    Archimedes Vascular Announces Close of Series A Financing led by Sherpa Healthcare Partners and Appoints Raymond W. Cohen as Chairman of its Board of Directors

    BIRMINGHAM, Ala. and BEIJING, June 23, 2025 /PRNewswire/ -- Archimedes Vascular, Inc., a pre-clinical stage medical device company developing an implant for the treatment of severe hypertension announced a $2.2 million Series A financing led by Sherpa Healthcare Partners. In conjunction with the financing, also announced the appointment of veteran medical device executive, Raymond W. Cohen to serve as chairman of its board of directors. "We are grateful to Sherpa and Ray for recognizing the potential of this exciting project and providing the funding to facilitate execution of

    6/23/25 9:00:00 AM ET
    $BSX
    $KMTS
    Medical/Dental Instruments
    Health Care

    Nalu Medical Appoints Veteran Medtech Executive Raymond W. Cohen Chairman of its Board of Directors

    Nalu Medical, Inc. ("Nalu") announced today the appointment of Raymond W. Cohen to serve as chairman of its board of directors. Raymond Cohen served as the chief executive officer and member of the board of directors of Nasdaq-listed Axonics, Inc., a medical device company he co-founded in 2013 and took public in late October 2018. Axonics ranked No. 1 on the Deloitte Technology Fast 500™ and the Financial Times ranking of the fastest growing companies in the Americas in 2021 and 2022. Cohen retired from Axonics following the November 2024 close of its $3.7 billion sale to Boston Scientific Corporation (NYSE:BSX). Following the sale of Axonics, Cohen was named chairman of the board of Son

    4/3/25 11:00:00 AM ET
    $BSX
    $KMTS
    Medical/Dental Instruments
    Health Care

    $BSX
    Financials

    Live finance-specific insights

    View All

    Boston Scientific announces participation in Bernstein's 42nd Annual Strategic Decisions Conference and conference call discussing second quarter 2026 results

    MARLBOROUGH, Mass., May 4, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) will participate in Bernstein's 42nd Annual Strategic Decisions Conference on Wednesday, May 27, 2026. Mike Mahoney, chairman and chief executive officer, and Janar Sathananthan, M.D., chief medical officer, Interventional Cardiology Therapies, will participate in a 50-minute question-and-answer session with the host analyst at approximately 8:00 a.m. ET. Additionally, the company will webcast its conference call discussing financial results and business highlights for the second quarter end

    5/4/26 8:00:00 AM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    Boston Scientific announces results for first quarter 2026

    MARLBOROUGH, Mass., April 22, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $5.203 billion during the first quarter of 2026, growing 11.6 percent on a reported basis and 9.4 percent on an operational1 and organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $1.341 billion or $0.90 per share (EPS), compared to $674 million or $0.45 per share a year ago, and achieved adjusted3 EPS of $0.80 for the period, compared to $0.75 a year ago. "Our global

    4/22/26 6:30:00 AM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    Boston Scientific announces conference call discussing first quarter 2026 results

    MARLBOROUGH, Mass., March 30, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) will webcast its conference call discussing financial results and business highlights for the first quarter ended March 31, 2026, on Wednesday, April 22, 2026, at 8:00 a.m. ET. The call will be hosted by Mike Mahoney, chairman and chief executive officer, and Jon Monson, executive vice president and chief financial officer. The company will issue a news release announcing financial results for the first quarter on April 22 prior to the conference call. A live webcast and replay for the ev

    3/30/26 8:00:00 AM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    $BSX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Boston Scientific Corporation (Amendment)

    SC 13G/A - BOSTON SCIENTIFIC CORP (0000885725) (Subject)

    2/13/24 5:00:46 PM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Boston Scientific Corporation (Amendment)

    SC 13G/A - BOSTON SCIENTIFIC CORP (0000885725) (Subject)

    2/9/24 11:49:03 AM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Boston Scientific Corporation (Amendment)

    SC 13G/A - BOSTON SCIENTIFIC CORP (0000885725) (Subject)

    2/9/24 8:35:54 AM ET
    $BSX
    Medical/Dental Instruments
    Health Care